What is ARQT's P/E ratio?

Arcutis Biotherapeutics Inc (ARQT) currently trades at a P/E ratio of 141.14.

Arcutis Biotherapeutics Inc reports a Return on Equity (ROE) of -1.25%.

What is ARQT's dividend yield?

Arcutis Biotherapeutics Inc offers a dividend yield of 0.00%.

What is ARQT's Quality Score?

Our AI rates ARQT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ARQT?

Our AI Timing Score for ARQT is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ARQT belong to?

Arcutis Biotherapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Arcutis Biotherapeutics Inc (ARQT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ARQT AI Analysis Summary

Our AI summary for ARQT: Arcutis Biotherapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 141.14, ROE of -1.25%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ARQT

Arcutis Biotherapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 95

USD 26.86

-1.13 (-4.04%) Day Change

Watchlist Portfolio Compare Chart

141.14

P/E

0.58

D/E

-1.3%

ROE

-0.5%

ROA

0.00%

Div Yield

ARCUTIS BIOTHERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 26.86 Price -1.13 (-4.04%) Day Change	NEWS SCORE: 95

ARQT, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	26.86
PBV / Sector	18.46 / 5.20
Earning Per Share	-0.02

PE / Sector	141.14 / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	34.43 M GREAT
Average 1W Daily Value	28.90 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-0.57 / 98.71
NPM Average (%) / Sector	-1,793.13 / -1,721.76
NPM Change Average (%) / Sector	-89.81 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-0.52 / 27.02
ROA Average (%) / Sector	-38.10 / -368.17
ROA Change Average (%) / Sector	-53.45 / 5,404.12
ROE (%) / Sector	-1.25 / 3.47
ROE Average (%) / Sector	-108.58 / 6.51
ROE Change Average (%) / Sector	-36.68 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:29
Symbol	ARQT
Name	ARCUTIS BIOTHERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	125.08 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3,501.08 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361

Phone: 805 418 5006

Website: https://www.arcutis.com

Employees: 354

Sector: Healthcare >> Biotechnology

Description: Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.